Back to Newsroom

Resverlogix Names Michael Sweeney, M.D., as Senior Vice President of Clinical Development

CALGARY, Nov. 3, 2014  /CNW/ –  Resverlogix Corp. (TSX:RVX) today announced the appointment of Michael T. Sweeney, M.D., as senior vice president of clinical development.

Dr. Sweeney, a cardiologist with extensive experience in pharmaceutical product development and marketing, will oversee clinical development programs for RVX-208 in cardiovascular disease (CVD), diabetes mellitus, and other indications. This will include the company’s Phase 2/3 trial of RVX-208 in patients with high-risk CVD with low HDL and diabetes mellitus.

Click here to read more